OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Subscribe To Our Newsletter & Stay Updated
